The study enrolled 25 patients. Median progression-free survival (mPFS) was 10.1 weeks (range 0.4-54.1) and median overall survival (mOS) was 21.6 weeks (range 0.4-84.1). Eighteen patients received at least 2 cycles, and achieved mPFS of 12.3 weeks and mOS of 28 weeks. Sixmonth survival rate was 44 % (11/25). Unsupervised clustering of patients grouped those with shortened survival together by their cytokine profile showed that only IL-6 had a significant difference (p < .001) between short-and long-term survivors. Conclusions Capecitabine plus PHY906 provides a safe and feasible salvage therapy after gemcitabine failure for APC. Role of IL-6 in tumor progression and tumor cachexia needs to be investigated with respect to its relation to pathophysiology of pancreatic cancer and development of anti-IL-6 therapeutics.
Introduction
The prognosis of patients with advanced pancreatic carcinoma (APC) is extremely poor despite numerous trials with palliative chemotherapy or radiotherapy [1] . Gemcitabine has been the standard of care in both adjuvant setting and metastatic settings while combination treatment carries more toxicity [2] . Currently there is no standard secondline chemotherapeutic drug in cases refractory to or recurring following gemcitabine. The median survival rate with best supportive care in patients who have failed gemcitabine is ~2 months. Nearly half of patients with gemcitabinepretreated disease may be candidates for further treatment. There is lack of data supporting the use of second-line
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Background Preclinical studies showed a Chinese botanical formula, PHY906, has synergistic anti-tumor activity with capecitabine. Our phase I study determined maximal tolerated dose of capecitabine 1,500 mg/m 2 BID day 1-7 and PHY906 800 mg BID day 1-4 every 2 weeks. We conducted this phase II study to explore the efficacy of capecitabine and PHY906 in patients with advanced pancreatic cancer who were previously treated with gemcitabine-based regimens. Methods Patients with pancreatic cancer and an Eastern Cooperative Oncology Group performance status of 0-2 received PHY906 and capecitabine. Toxicity was assessed per NCI-CTCAE v3.0 and response per response evaluation criteria in solid tumors q 6 weeks. Correlative studies of cytokines, chemokines and growth factors were tested using a cytometric bead array. Quality of life was assessed by utilizing Edmonton symptom assessment system. The primary objective was overall survival. therapy compared with best supportive care. The most acceptable approach for patients who have already received gemcitabine-based chemotherapy is fluoropyrimidine-based chemotherapy and more specifically capecitabine, 5-FU/ leucovorin/oxaliplatin (OFF) and capecitabine plus oxaliplatin (CapeOx). However, the only established therapeutic choice is OFF regimen according to the Charité Onkologie (CONKO)-003 trial [3] . Therefore, there is a continuing need for clinical trials with a new agent for advanced pancreatic cancer in cases of gemcitabine failure.
Capecitabine, an oral fluoropyrimidine carbamate designed to generate 5-FU preferentially in tumor tissue through exploitation of high intratumoral concentrations of thymidine phosphorylase [4] , has been investigated in patients with pancreatic cancer as a single agent [5, 6] or in combination with chemotherapy and radiotherapy [4, 7] . Cartwright et al. [5] demonstrated that capecitabine 1,250 mg/m 2 BID administered in a 14/7 schedule had clinically significant beneficial effects in chemotherapy-naïve APC patients and was relatively well-tolerated . Boeck et al. [6] also showed capecitabine 1,250 mg/m 2 BID in a 14/7 schedule to be effective in controlling disease in gemcitabine-pretreated patients. Scheithauer et al. [8] found that a 7/7 intermittent dosing (1,750 mg/m 2 BID = total daily dose of 3,500 mg/m 2 ) was just as active as a 14/7 dosing when used in combination with oxaliplatin in CRC patients. The National Comprehensive Cancer Network guidelines for APC recommend capecitabine as second-line treatment [9] .
PHY906 is a botanical formulation composed of four distinct herbs: Scutellaria baicalensis Georgi, Glycyrrhiza uralensis Fisch., Ziziphus jujuba Mill., and Paeonia lactiflora Pall [10, 11] . This herbal formula has been used in Asia to treat a variety of ailments such as abdominal cramps, fever, headache, vomiting, thirst and diarrhea for over 1,700 years [12, 13] . Anti-diarrheal activity was demonstrated in our previous clinical studies of PHY906 and irinotecan, PHY906 and 5-FU/leucovorin in colorectal cancer (CRC), PHY906 and capecitabine in hepatocellular carcinoma (HCC) and phase I study of PHY906 and capecitabine in pancreatic cancer [11] [12] [13] . PHY906 was well tolerated up to 2.4 g/day, and the frequency of diarrhea and vomiting was significantly lower with PHY906 than with placebo treatment.
Beyond the cytoprotective benefit of PHY906, PHY906 also potentiates the effect of chemotherapy in preclinical models [14] . In a preclinical tumor-bearing mouse model using PANC-1 tumors, PHY906 alone has little, if any, cytotoxic anti-tumor activity, but it potentiates the action of capecitabine when given in combination [15] (Fig. 1 ). There were no difference in mouse bodyweight change or anti-tumor activity between the daily and the intermitted schedules of PHY906 when co-administrated with capecitabine. However, we observed one mortality in our mouse liver cancer model (N = 5) after 14 consecutive day of PHY906 administration with capecitabine. Therefore, the proposed schedule was used in the clinical study. Our phase I study of PHY906 and capecitabine in patients with APC and other GI malignancies suggested that PHY906 could increase the therapeutic index of capecitabine in patients by reducing side effects such as diarrhea and resulted in a disease control rate of 58 % with one PR and thirteen SD out of 24 patients [16] . These previous results were sufficiently compelling to lead us to conduct a phase II study to evaluate the efficacy of PHY906 in combination with capecitabine (PHY906 800 mg BID days 1-4 and capecitabine 1,500 mg/m 2 BID days 1-7 of a 14-day cycle) in gemcitabine-pretreated patients with advanced pancreatic cancer.
Patients and methods

Patient selection
The inclusion criteria for this study were (1) histologically or cytologically proven pancreatic adenocarcinoma and unresectable locally advanced or metastatic disease; (2) at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST); (3) prior chemotherapy with gemcitabine-based chemotherapy; (4) the ability to take oral medications; (5) bilirubin ≤2 × UNL; aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤2.5 × UNL (if liver function abnormalities were due to underlying liver metastasis, then AST and/or ALT may be ≤5 × UNL)].
The exclusion criteria for this study were patients who (1) had received chemotherapy or radiotherapy within 3 weeks; (2) had previously received an oral fluoropyrimidine except as a radiosensitizer; (3) had central nervous system metastases; (4) had an active infection or uncontrolled concurrent medical illness; (5) had a history of other malignancies; (6) were pregnant or lactating; (7) had severe neurological impairment, a mental disorder or any severe drug-induced allergy.
The protocol and associated informed consent forms were reviewed by the Investigational Review Boards (IRB) and approved prior to study initiation. This study was conducted in accordance with Good Clinical Practice guidelines of the International Conference on Harmonization, and the Declaration of Helsinki.
Treatment plan
Based on our phase I results, we chose PHY906 800 mg BID days 1-4 and capecitabine 1,500 mg/m 2 BID days 1-7 of a 14-day cycle to assess the clinical activity and tolerability of the combination in patients with gemcitabinerefractory pancreatic cancer [16] .
Toxicity was assessed per NCI-CTCAE v3.0 [17] . Dose reduction and omission criteria for both agents were defined for hematological and non-hematological toxicity. Doses of capecitabine were omitted if the ANC was <500 μL or platelets were <25,000 μL, and then reduced by 250 mg/m 2 if the ANC recovered to ≥1,000 μL or if the platelet count was ≥50,000 μL. There was no replacement of missed doses of capecitabine. Whenever capecitabine was omitted, PHY906 was also held during that period. Treatment was also omitted if any non-hematological toxicity of grade 2 or higher emerged and had not resolved to baseline or ≤grade 1 by scheduled start of treatment. Oral prophylactic antiemetics were administered 30 min prior to each dose of capecitabine. Pyridoxine and emollients were routinely prescribed for all patients who entered the study.
Assessment of efficacy
All patients were included in efficacy measurements on an intent-to-treat basis. Tumor responses were evaluated according to the RECIST Criteria [18] . QOL was assessed by utilizing a validated system called as Edmonton Symptom Assessment System, a clinical assessment scale commonly used in palliative care settings, at baseline and then before each cycle [19] . A tenth scale was included for any other symptom of particular importance to the patient.
Investigational studies/laboratory correlates
Research bloods (one 5-mL heparinized tubes; green) were collected by vena puncture prior to each of the treatments (between day −7 to day 1), day 8 and before the start of cycle 2. Blood samples were centrifuged to obtain plasma. Plasma collected from patients was stored at −80 °C, and then analyzed for factors using the BD™CBA flex kits from BD with the BD FACSArray™. Cytometric bead array (CBA), commonly referred to as a multiplexed bead assay, is a flow cytometry-based assay for the detection of human cytokines from cell supernatants or serum samples as previously published [20] . Cytokines measured included interleukins (IL): IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, interferon gamma (IFNγ), RANTES (also known as CCL5 and SISd), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte-colony-stimulating factor (G-CSF or GCSF), monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interferon gamma-induced protein 10 (IP-10) and angiogenin (Ang). Data were generated using the FCAPArray™ software.
Statistical analysis
The Primary objective for the phase II portion of this trial was to determine the overall survival time (OS) for patients with gemcitabine-refractory APC treated with PHY906 + capecitabine. The phase II portion of this study follows a Simon two-stage design with an early stopping rule. The study was powered to improve median survival of these patients from 2 to 4 months. The primary outcome was the number of patients who survived up to three months. A two-month median survival would result in 35 % patients surviving until 3 months. This calculation assumes an exponential survival distribution. We took this 35 % rate to be our null hypothesis. If the median survival could be improved in this protocol to 4 months, then approximately 60 % of patients would survive until 3 months. The 60 % three-month survival rate was the alternative hypothesis. The design of the phase II portion of this protocol called for enrolling up to 24 patients. If 4 or more of the first 12 patients survived at least 3 months, then we planned to enroll an additional 12 patients for a total of 24. If 12 or more of the 24 survived at least 3 months, then we rejected the 35 % survival rate in favor of the 60 % rate. This design has significance level .087 and power .86. There is probability of .58 of stopping early under the 35 % three-month survival rate. Overall survival was measured as the time from start of treatment to the date of death or the last date the patient was known to be alive and analyzed by using Kaplan-Meier analysis. All patients who receive any study treatment were included in the final summaries and listing of safety data.
Results
Patient characteristics
A total of 25 patients were enrolled in the study from December 2005 to December 2008 at Yale Cancer Center. All patients received treatment, and three patients did not finish the first cycle. All patients were evaluated for toxicity and survival, 20 patients received 2 cycles or above were evaluated for response. Among the 25 enrolled on the study, 15 were men and 10 were women; 24 patients with ECOG PS of 0-1, and the median age was 64 years (range 45-84 years). All patients in this study were previously treated with gemcitabine single agent or in combinations; five (20 %) patients had prior adjuvant gemcitabine after surgery (Whipple) and two out of these five patients also received local radiotherapy with capecitabine as a radiosensitizer. Among 25 patients, 21 had metastatic disease upon enrolling, and 4 had locally advanced, unresectable or recurrent disease. The characteristics of the 25 patients are presented in Table 1 .
Treatment compliance and toxicities
A total of 137 cycles were delivered with a median of 5 cycles per patient (range 1-19 cycles). Twenty patients completed at least 2 cycles of treatment. The most common reason for discontinuation was disease progression (14 patients; 56 %) followed by drug-related toxicity (8 patients; 32 %). Table 2 lists the common hematological and non-hematological treatment-related toxicities. Eight patients discontinued treatment due to toxicities, two due to non-treatment-related infections (cholangitis, pneumonia) and one patient died (unrelated; significant cardiac history).
Efficacy
Two of 20 evaluable patients (10 %) had a partial response (confirmed) as the best response during treatment period, and 11 patients (55 %) had stable disease. For all intended-to-treat patients, median progression-free survival was 10.1 weeks (range 0.4-54.1 weeks); median overall survival was 21.6 weeks (range 0.4-84.1 weeks) (Table 3 ; Fig. 2 ). For patients who tolerated 2 cycles or above, the mPFS was 12.3 weeks (range 4.2-51 weeks) and the mOS was 28 weeks (range 7-84.1 weeks) (Fig. 2) . Three-month survival was reached in 68 % patients (17/25). Six-month survival rate was 44 % (11/25) and nine-month survival rate reached 22 %.
Baseline CA 19-9 data were available for all 20 evaluable patients and the median CA 19-9 U/mL level was 727.5 (range 4-19,012). Univariate regression analysis was performed and there was no correlation noted between baseline CA 19-9 and progression-free survival. 
QOL
The Edmonton Symptom Assessment scale (ESAS) was used. Twenty patients reported significantly impaired QOL on nine of 9 scales/items (80 % response) at the beginning of cycle 2 (median 1; range 0-4) and at the beginning of cycle 3 (median 1; range 0-5) compared to baseline (median 2; range 0-8). Fatigue, loss of appetite, nausea and impaired sense of well-being were the most improved items noticed improved by 4+ points. The patients who remained on the study longer continued to maintain their improvement in QOL: at cycle 6 (median 0; range 0-3), cycle 9 (median 0; range 0-3), cycle 12 (median 0; range 0-5), cycle 15 (median 0; range 0-3) and cycle 18 (median 1; range 0-2). Scores were not available for most of the patients at the time of death, and therefore, no formal analysis was performed. About twelve patients have improved pain control either defined by pain scale or amount of analgesics, resulting in a response rate of 48 %. Only two patients had diarrhea while 11 patients noticed either improvement in diarrhea or no need to take anti-diarrheal medications (44 %). Depression was improved in four patients without use of antidepressants (16 %).
Correlative cytokine study
Correlative studies showed that plasma markers varied among patients and each one, by itself, did not appear to be correlated with response, survival or toxicity. Preliminary unsupervised clustering of patients grouped those with shortened survival versus prolonged survival together by their cytokine profile was performed. Cytokine cluster analysis demonstrated the level of IL-6 is negatively correlative with the overall survival, and the higher level correlates with a shorter length of survival (p < .001). Figure 3 showed the IL-6 level is negatively correlative with the overall survival.
Discussion
Our study is the first-in-human clinical study that evaluated the combination of botanical formulation PHY906 and capecitabine in patients with gemcitabine-refractory APC and met its end point. In the majority of patients, pancreatic cancer remains a chemoresistant cancer, and doublet combination regimens have produced, at best, marginal results over single-agent gemcitabine but at the cost of more toxicity. The median survival with best supportive care in patients who have failed gemcitabine therapy is ~2 months [21] . Approximately half of the patients with gemcitabinepretreated disease may be candidates for further treatment. Preclinical models demonstrated synergistic effect of PHY906 on cytotoxic chemotherapy such as irinotecan, capecitabine, 5-FU, etc. [15, 16, 22] . Our efficacy data suggest that PHY906 potentiates the anti-tumor effect of capecitabine. All patients in this study were previously treated with gemcitabine single agent or in combinations. Overall, this combination was well tolerated and resulted in a median overall survival of 22 weeks for all intendedto-treat patients, 28 weeks for patients received ≥2 cycles. The two patients who derived partial response had surprisingly long overall survival with persistent improved QOL, survival length of 69 and 84 weeks.
Our patients also tolerated a much higher dose than an average American patient. Recent data using mathematical modeling suggest that drug delivery beyond 7 days contributes to toxicity with diminishing anticancer effects [23] . Traina and colleagues achieved an MTD of capecitabine of 2,000 mg BID fixed dosing for seven consecutive days followed by a seven-day rest period in breast cancer patients. In this study, we used BSA-based dosing of capecitabine and have shown the MTD to be 1,500 mg/m 2 BID in a 7/7 dosing schedule. Compared to the fixed dose 7/7 used by Traina et al., the average BSA in our patients was 1.88 mg/ m 2 , yielding an median starting dose of 2,725 mg BID at the MTD and for the whole study, significantly more than the 2,000 mg BID fixed dosing. Compared to conventional 14/7 capecitabine dosing of 1,250 mg/m 2 BID, our 7/7 schedule of 1,500 mg/m 2 BID achieves a 90 % relative dose intensity (1,000 mg/m 2 less per week) and may be a more tolerable schedule, especially when used in conjunction with PHY906.
In traditional eastern herbal medicine, multiple herbs are used together either to induce a synergistic effect, enhance the efficacy or reduce the side effects of the formulation. This combination had demonstrated some anti-diarrhea effects in phase I study in several GI malignancies [16] . In this phase II study, we also observed a lower incidence of grade ≥2 HFS and diarrhea. This triggered us to further analyze the cytokine data which revealed less expression of several cytokines in patients with higher HFS scores (Fig. 4) .
Biochemical studies reveal that the PHY906 formulation possesses a wide range of pharmacological activities. The potential mechanism(s) of action of PHY906 include (1) enhancement of cellular uptake of chemotherapeutic agents via inhibition of MDR (multi-drug resistance) mechanisms; (2) modulation of NF-kB activity; (3) inhibition of MMP (matrix metalloproteinase) activity; and (4) inhibition of angiogenesis [12, 13, 16] . Therefore, correlative studies in this study measured chemokines such as IL-2, TNF-a, etc. as surrogates for NF-kB expression, to further elucidate the effects of PHY906. The cytokine/ chemokine cluster analysis demonstrated that IL-6 could be used as a prognostic marker. IL-6 is a multipotent cytokine exerting numerous biological activities and its serum levels are elevated in many solid tumors, including lung cancer, Unsupervised Clustering renal cell carcinoma and ovarian cancer [24, 25] . In our study, unsupervised clustering of patients grouped those with shortened survival versus prolonged survival together by their cytokine profile demonstrated the level of IL-6 is negatively correlated with the overall survival, the higher level correlates with a shorter length of survival (p < .001) between short-and long-term survivors. It is not yet clear whether the increased serum IL-6 levels in PC patients were produced by the cancer cells or tumor-associated host cells such as fibroblasts and macrophages [26] . Excessive amounts of IL-6 in serum may play various roles in tumor progression, including metastasis and clinical manifestations such as weight loss [27] . Anti-IL-6 or anti-IL-6 receptor antibodies could be useful in treating patients with IL-6-producing tumors [28] . The options for metastatic pancreatic cancer patients are changing over the last 2 years with the positive results of FOLFIRINOX and gemcitabine-nab-paclitaxel studies [29] . However, FOLFIRINOX regimen is suitable for selected fit patients, and nab-paclitaxel is associated with neuropathy, which will not make OFF regimen (oxaliplatin-based) an ideal therapy for those with existing nerve damage. Therefore, capecitabine alone and its combinations, such as the one tested in our study, offer an acceptable option for gemcitabine-refractory patients.
In conclusion, this is the first phase II study that evaluated an herbal drug in combination with chemotherapy for the treatment of APC. Although the number of patients is small, this study proved the hypothesis generated from preclinical as well as phase I studies. We believe that given the manageable toxicity, capecitabine-PHY906 has a role in patients with gemcitabine-pretreated APC and warrant further investigation. Moreover, studies are required to establish whether IL-6, either alone or in concert with other cytokines, is involved in the pathophysiology of pancreatic cancer, and finally, anti-IL-6 therapeutics could serve as a useful tool for improving symptoms in these patients with high IL-6 levels.
